TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05620771
Drug: Y90 + TKI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive TKI for 21 days after standard of care therapy is complete.
Study: NCT04782960
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 saline
Study: NCT06424665
Drug: FZ-AD005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every 21 days for 1 cycle. Subjects will receive an intravenous infusion of FZ-AD005 until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
Study: NCT06162221
Drug: RMC-6291
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT06162221
Drug: RMC-9805
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT05505916
Drug: KVD900 600 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: KVD900 Tablet 600 mg (2 x 300 mg)
Study: NCT04652726
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile normal saline (0.9% sodium chloride in water for subcutaneous injection)
Study: NCT05033314
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo daily
Study: NCT04541147
Drug: Analgesics
Normalized name: ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: standardization of post-operative analgesics (narcotics and non-narcotic medication).~* Oxycodone solution or tablet (depending on age of patient) at 0.05-0.1 mg/kg/dose every 6hrs; max 5mg (obese/OSA); prescribe 30 doses~* Acetaminophen 10-15 mg/kg/dose every 6 hours; max 500mg per dose; prescribe 56 doses (over the counter medication)~* Ibuprofen 5-10 mg/kg/dose every 6 hours; max 200 mg/dose; prescribe 56 doses (over the counter medication)
Study: NCT06286397
Drug: Vehicle Cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of a vehicle cream to the natal cleft twice daily for 12 weeks
Study: NCT06204094
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2, PO, BID, d1-14 of each cycle\*8cycles
Study: NCT05750680
Drug: DOACs
Normalized name: Doans
Approvals — FDA: no, EMA: no, PMDA: no
Description: outpatients visited in anticoagulation clinics with a prescription of DOAC for atrial fibrillation and venous thromboembolism and concomitant antiepileptic drug will perform a blood draw for measurement of dabigatran, rivaroxaban, apixaban and edoxaban
Study: NCT04711863
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 200 mg per day as tolerated until discharge from community treatment center or for approximately 10 days
Study: NCT06240455
Drug: WP1302
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).
Study: NCT06240455
Drug: WP1302 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each arm will be treated with methimazole. During the MMI tapering period, commences the MMI weaning by reducing the original dosage by 50%. This adjusted dose is to be administered over a two-week duration. Continue this dose reduction in the subsequent 2-week durations until achieving a dose of 2.5 mg/day or lower. Upon reaching this threshold, MMI is to be discontinued (withdrawal).
Study: NCT04528771
Drug: SNO
Normalized name: Sno Pilo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six-hour SNO treatment by inhalation at a sequential increasing dose regimen of 20 ppm x 2 hr, 40 ppm x 2 hr, 80 ppm x 2 hr. Patient care and follow-up during and after ENO administration will follow the critical care clinical SOPs developed by our institution (attached in Additional Information), which are consistent with the guidelines set out by the World Health Organization.
Study: NCT06332430
Drug: CAN2109
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAN2109 IT injection (once every 3 weeks)
Study: NCT05642923
Drug: Synthetic Vitamin B1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic Vitamin B1 400 mg per day
Study: NCT05695664
Drug: Ibuprofen 800 mg
Normalized name: ibuprofen 800 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous injection of ibuprofen 800 mg
Study: NCT05695664
Drug: Ketorolac Injection
Normalized name: ketorolac Injection
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous injection of Ketorolac 30 mg
Study: NCT04288115
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will be instructed to start the study medication the day after randomization. The study medication will be taken orally once a day.
Study: NCT04724447
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo equivalent of 900mg/day VGCV
Study: NCT06561698
Drug: Minocycline,Metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics for H. pylori eradication
Study: NCT05936658
Drug: [F-18]Florastamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of \[F-18\]Florastamin at 10 ± 1 mCi is intravenously administered only to the subjects who meet the inclusion/exclusion criteria, and then \[F-18\]Florastamin PET/CT imaging is performed from the head to thigh after 105 ± 15 minutes (care should be taken to prevent extravasation of the radiopharmaceutical product).
Study: NCT05549778
Drug: Polaprezinc group
Normalized name: polaprezinc
DrugBank: Polaprezinc (DB09221)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abiraterone plus Polaprezinc for 6 months
Study: NCT05549778
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abiraterone, radio- or chemotherapy
Study: NCT05567458
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06421818
Drug: Baitouweng Tang
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baitouweng Decoction is composed of four herbs: Baitouweng, Rhizoma coptidis, Phellodendri huangbai and Qin Pi.
Study: NCT06300411
Drug: SRG-514
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRG-514 monotherapy
Study: NCT06475846
Drug: HRS5580
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS5580; low dose
Study: NCT06475846
Drug: HRS5580
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS5580; middle dose
Study: NCT05636774
Drug: Heart failure medication
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Sacubitril/valsartan, Ivabradine, Ferric carboxymaltose and/or Empagliflozin.
Study: NCT05636774
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tables / infusion
Study: NCT04985942
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching capsules administered orally, once daily.
Study: NCT05351398
Drug: Traditional group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with stage III gastric cancer who need neoadjuvant chemotherapy before radical surgery are recruited. In this group, patients are treated with the SOX regimen.
Study: NCT06205420
Drug: Injectable giomer restoration
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: The teeth affected with enamel hypoplasia will be prepared by removing all defective enamel to place the restorations on sound tooth structure as recommended by the IAPD.~A tooth-by-tooth approach will be employed, where adjacent teeth will be isolated with Teflon tape before selective enamel etching. Selective etching of cut enamel will be done for 15 seconds using 37% phosphoric acid gel. Self-etch adhesive system will be used and an injectable giomer restoration will be injected in the accurately positioned transparent clear stent through the small channels created by the tip of the restoration syringe in the incisal edge to restore the affected teeth.~Curing will be done on the incisal and labial aspects for 20 seconds and will be repeated after clear stent removal for additional 20 seconds. After removal of the clear stent from the patient's mouth, the restoration sprue as well as excess polymerized restoration will be scrapped off with a scalpel.
Study: NCT05861440
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: adjunct steroid per study protocol
Study: NCT05861440
Drug: standard anti-tuberculosis agents
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard anti-tuberculosis agents
Study: NCT06317662
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06317662
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT06317662
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO or NG or IV
Study: NCT06317662
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO or NG
Study: NCT06317662
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT or IV or PO or NG
Study: NCT06317662
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO or NG
Study: NCT06317662
Drug: Therapeutic Hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IT
Study: NCT06635538
Drug: Clomiphene Citrate (CC) 100 mg/day from D1
Approvals — FDA: no, EMA: no, PMDA: no
Description: On day 2 or 3 of the menstrual cycle or after 5 days of pill-free interval, the patients will start oral administration of Clomiphene Citrate 100/day continuing up to and including the day of ovulation triggering
Study: NCT06635226
Drug: ID110521156
Approvals — FDA: no, EMA: no, PMDA: no
Description: ID110521156 capsules taken orally once daily
Study: NCT06635226
Drug: Placebo of 110521156
Approvals — FDA: no, EMA: no, PMDA: no
Description: ID110521156 placebo capsules taken orally once daily
Study: NCT04955470
Drug: Normal Saline 0.9% Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 0.9% normal saline solution will be infused over a 40 minute period.
Study: NCT06027606
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practice inhaler primarily used in training scenarios so looks identical to medical inhalers
Study: NCT05882292
Drug: ABN401
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABN401 800 mg will be administered orally once daily immediately after a meal \[should be within 1 hour post-meal (fed state)\] at approximately the same time each day in a 21-day cycle.
Study: NCT06451159
Drug: Chemotherapy: cyclophosphamide (CYC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive one 3-day cycle of lymphodepletion with CYC 300 mg/m2 prior to administration of KYV-101.
Study: NCT06786936
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium chloride 0.9% for injection will be used as a placebo. A 1ml volume will be drawn up into a suitable sized syringe and labelled in accordance with standard practice at site. The dose will be administered as a subcutaneous injection in line with the Secukinumab/ Bimekizumab/ Ixekizumab dosing regimen. No dose adjustments are permitted.
Study: NCT05364515
Drug: PRGF
Normalized name: Platelet-Rich Growth Factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma Rich in Growth Factors (PRGF) is a mixture of proteins and growth factors obtained from the blood of the patient.~Four PRGF infiltrations (two weeks between each infiltration). Then, application of topical PRGF serum (on alternate basis)
Study: NCT05961644
Drug: 0.9% Chloride Injection Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride injected subcutaneously, 10 ml daily, for 2-3 consecutive days
Study: NCT05051761
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT06132828
Drug: DR30206
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive DR30206 intravenously
Study: NCT06630806
Drug: SAR446523
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Powder for solution for injection; Route of administration: Subcutaneous (SC)
Study: NCT06630845
Drug: Fluorodeoxyglucose F18
Normalized name: fluorodeoxyglucose F18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV as part of routine imaging
Study: NCT06629597
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be administered orally at 1000 mg/m2 twice a day (BID) on Days 1 to 14 of each 3-week cycle
Study: NCT06365437
Drug: Corticosteroids (CS)
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care Concomitant Immunosuppression
Study: NCT06336161
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: to compare between Ultrasound-Guided ESPB and Ultrasound-Guided CEI for postoperative pain relief in patients who underwent lumbosacral surgeries.
Study: NCT05650528
Drug: QG101-23-0 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single and Multiple Dose for oral
Study: NCT05650528
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single and Multiple Dose for oral
Study: NCT06631170
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream is applied once daily for 4 weeks
Study: NCT05213507
Drug: aerosol inhaled Amikacin Sulfate Injection
Normalized name: amikacin Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4g Amikacin sulfate injection + 5ml saline, aerosol inhalation, b.i.d., 7-10 days per month, for 3 months.
Study: NCT05049733
Drug: CBD 1mg/Kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will ingest soft gel tablets containing CBD 1mg/Kg
Study: NCT05049733
Drug: CBD 2mg/Kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will ingest soft gel tablets containing CBD 2mg/Kg
Study: NCT05049733
Drug: CBD 4mg/Kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will ingest soft gel tablets containing CBD 4mg/Kg
Study: NCT05049733
Drug: Placebo CBD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will ingest soft gel tablets containing placebo for CBD
Study: NCT06148389
Drug: STSA-1301 subcutaneous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive the administration dose on Day 0 following protocol requirements.
Study: NCT06148389
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive the administration dose on Day 0 following protocol requirements.
Study: NCT04979130
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide placebo, solution for injection, 1.5 mL pre-filled PDS290 pen-injector provided by Novo Nordisk.
Study: NCT04767217
Drug: artemether-lumefantrine (ALN)
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessing the efficacy on current 1st line antimalarial, and an alternative 1st line or 2nd line medicine
Study: NCT05680740
Drug: VTAMA® (tapinarof) Cream 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: VTAMA® (tapinarof) Cream 1% applied topically once daily
Study: NCT04993677
Drug: SEA-CD40
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given into the vein (IV; intravenously); schedule is cohort-specific
Study: NCT05896228
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Acetaminophen orally (PO) prior to Iber-KDd therapy as follows:~* Cycles 1 and 2: 650 mg/dose on Days 1, 8, 15, and 22~* Cycles 3 through 6: 650 mg/dose on Days 1 and 15~* Cycles 7 and 8: 650 mg/dose on Day 1.
Study: NCT04973189
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of matching SHR-1707 placebo by intravenous (IV) infusion in healthy young adults.
Study: NCT04973189
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of matching SHR-1707 placebo by intravenous (IV) infusion in elderly subjects.
Study: NCT05275660
Drug: HFB30132A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to HFB30132A will be administered dose 1 in cohort 1. Participants in Cohort 2 will receive HFB30132A dose 2.
Study: NCT06801522
Drug: Adrenaline nasal pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline is direct acting, non selective, adrenergic agonist binding with alpha and beta receptors both, used for vasoconstriction to decrease nasal bleeding.
Study: NCT06297434
Drug: J2H-1702
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, once daily before meals
Study: NCT05481879
Drug: DYNE-101
Normalized name: Barrier-Dyne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by IV infusion
Study: NCT05481879
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by IV infusion
Study: NCT06400771
Drug: DNP007
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNP007 is a therapeutic agent that can replace calcineurin inhibitor (CNI), which is a representative factor that can be used as an adhesive for extrahepatic long-term survival patches such as after liver transplantation in patients with liver disease and hepatocellular carcinoma, adult metabolic status, neoplasms, etc. , an anti-ICAM-1 mouse monoclonal minority, is a humanized Fab region that humanizes MD-3 and the Fc region of human IgG1, separated by translational engineering.
Study: NCT05733403
Drug: isotonic solution
Normalized name: Isotonic solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic solutions are IV fluids that have a similar concentration of dissolved particles as blood.
Study: NCT06518694
Drug: Βeta-Blockers discontinued (with tapering)
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The experimental group will undergo discontinuation of their beta-blockers treatment during the study period.~The tapering of beta-blocker will start on the day after randomisation and is based on a reduction by half-dose every 48 hours (1/2 maximally recommended dose for 48 hours, then ¼ maximally recommended dose for 48 hours) until reaching the minimal recommended dosage (1/8 maximally recommended dose) for 48 hours before complete interruption of treatment. Consequently, the tapering will not be needed in patients already receiving the minimal recommended dosage (i.e., 1/8 dose) at inclusion, and these patients will be instructed to stop taking beta-blockers the day after randomisation.
Study: NCT06226662
Drug: NM8074
Approvals — FDA: no, EMA: no, PMDA: no
Description: NM8074 will be administered as an intravenous infusion. In Cohort 1, all subjects will be administered 20 mg/kg of NM8074 intravenously every two weeks for a total of 7 doses from Day 1 to Day 85 of the Treatment Period.
Study: NCT06226662
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline Placebo will be administered as an intravenous infusion. In Cohort 2, all subjects will be administered saline placebo intravenously every two weeks for a total of 7 doses from Day 1 to Day 85 of the Treatment Period.
Study: NCT06453551
Drug: TRN501 - Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
Study: NCT06453551
Drug: TRN501 - Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
Study: NCT05508074
Drug: IFB-088 50mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tested product
Study: NCT05508074
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04961970
Drug: oxaliplatin , fluorouracil, and leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
Study: NCT06453551
Drug: TRN501 - Dose 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
Study: NCT06453551
Drug: TRN501 - Dose 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
Study: NCT05660473
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alkylating agent
Study: NCT05660473
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Antifolate antineoplastic drug
Study: NCT05792865
Drug: No paxlovid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients not treated with PAXLOVID will be included in this group. This study is a non-interventional observational study, and no intervention measures were applied to the clinical diagnosis and treatment process of hospitalized COVID-19 patients. The use of Paxlovid is completely decided by the clinical doctors based on the patients' condition and clinical experience.
Study: NCT06016972
Drug: Experimental: QLS-111 ophthalmic solution, (0.03%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QLS-111 ophthalmic solution, (0.03%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.